What is the 13F Pro Quality Score for AIMD?

13F Pro ranks Ainos, Inc. (AIMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AIMD's current score at https://13fpro.ai/research/AIMD (free sign-up required for the full ranking).

Which hedge funds own the most AIMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AIMD include GEODE CAPITAL MANAGEMENT,, Mariner,, BOOTHBAY FUND MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AIMD as soon as new 13F filings post.

Where does 13F Pro source AIMD data?

All Ainos, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ainos, Inc. files with the SEC under CIK 1014763. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AIMD in?

Ainos, Inc. (AIMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AIMD research updated on 13F Pro?

AIMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ainos, Inc.(AIMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1014763 AIMD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AIMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ainos, Inc. (AIMD), a Healthcare sector company. AIMD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Ainos, Inc. reports quarterly revenue of $161.00, net income of $-2.5M, free cash flow of $-992.0K. Top institutional holders of AIMD by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Mariner,, BOOTHBAY FUND MANAGEMENT,, based on the most recent SEC filings. AIMD trades on the Nasdaq exchange and files with the SEC under CIK 1014763. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ainos, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$161.00

Net Income

Q1 2026

$-2.5M

Free Cash Flow

Q1 2026

$-992.0K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-83.0% YoY

$20.7KFY 2024

FY21 $594.6KFY22 $3.5MFY23 $122.1KFY24 $20.7K

Net Income

-7.9% YoY

$-14.9MFY 2024

FY21 $-3.9MFY22 $-14.0MFY23 $-13.8MFY24 $-14.9M

Operating Income

-4.8% YoY

$-13.8MFY 2024

FY21 $-3.9MFY22 $-14.0MFY23 $-13.2MFY24 $-13.8M

EPS (Diluted)

-365.5% YoY

$-7.82FY 2024

FY21 —FY22 —FY23 $-1.68FY24 $-7.82

Total Assets

-9.5% YoY

$28.8MFY 2024

FY21 $40.8MFY22 $37.1MFY23 $31.8MFY24 $28.8M

Op. Cash Flow

-23.7% YoY

$-5.8MFY 2024

FY21 $-1.2MFY22 $-3.0MFY23 $-4.7MFY24 $-5.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2017
Revenue	$20.7K -83.0%	$122.1K -96.5%	$3.5M +492.0%	$594.6K +4968.3%	$11.7K -95.3%	$250.9K
Net Income	$-14.9M -7.9%	$-13.8M +1.7%	$-14.0M -260.2%	$-3.9M -145.9%	$-1.6M -156.1%	$-617.4K
Operating Income	$-13.8M -4.8%	$-13.2M +5.5%	$-14.0M -261.4%	$-3.9M -144.7%	$-1.6M -172.6%	$-579.8K
EPS (Diluted)	$-7.82 -365.5%	$-1.68	—	—	—	—
Total Assets	$28.8M -9.5%	$31.8M -14.2%	$37.1M -9.1%	$40.8M +6742.2%	$596.6K -74.0%	$2.3M
Operating Cash Flow	$-5.8M -23.7%	$-4.7M -54.4%	$-3.0M -143.3%	$-1.2M -37.4%	$-909.5K -87.7%	$-484.6K

AI Insight: AIMD Financial Trends

Pre-revenue biotech burning cash steadily with equity base eroding 71% from Q2 2024 to Q1 2026.

• Net losses narrowed from $5M in Q4 2024 to $2M in Q1 2026; operating cash burn flat at $1M per quarter.

• Equity declined from $21M (Q2 2024) to $6M (Q1 2026), a 71% contraction, signaling capital depletion.

⚠ Zero revenue across all periods. Company has <2 quarters of equity remaining at current burn rate.

⚠ Q1 2026 net loss of $2M represents best quarterly result, but sustainability unclear without milestone or funding.

AI Insight: AIMD Ratio Trends

Ainos remains deeply unprofitable across all return metrics, with ROE deteriorating to −172.9% in Q1 2026 despite modest ROA improvement.

• ROA improved from −85.6% in Q4 2025 to −44.6% in Q1 2026, signaling reduced per-asset losses.

• ROE worsened to −172.9% in Q1 2026 from −116.7% in Q3 2025, indicating shareholder value destruction accelerated.

⚠ Sustained negative returns across all quarters since Q2 2024 with no path to profitability visible in data.

⚠ ROA volatility (ranging −36.0% to −85.6%) suggests inconsistent operational performance or accounting timing.

Get alerted when AIMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ainos, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AIMD

GEODE CAPITAL MANAGEMENT, LLC
$73.8K53,074 sh
Mariner, LLC
$42.8K30,800 sh
BOOTHBAY FUND MANAGEMENT, LLC
$34.8K25,000 sh
Keystone Financial Group
$20.2K14,550 sh
VANGUARD FIDUCIARY TRUST CO
$19.7K14,169 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.9K9,281 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$6.5K55,837 sh
Tower Research Capital LLC (TRC)
$6.2K4,441 sh
BlackRock, Inc.
$4.3K3,065 sh
Seneschal Advisors, LLC
$2.5K1,800 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$73.8K	53,074
Mariner, LLC	$42.8K	30,800
BOOTHBAY FUND MANAGEMENT, LLC	$34.8K	25,000
Keystone Financial Group	$20.2K	14,550
VANGUARD FIDUCIARY TRUST CO	$19.7K	14,169
VANGUARD CAPITAL MANAGEMENT LLC	$12.9K	9,281
HEIGHTS CAPITAL MANAGEMENT, INC	$6.5K	55,837
Tower Research Capital LLC (TRC)	$6.2K	4,441
BlackRock, Inc.	$4.3K	3,065
Seneschal Advisors, LLC	$2.5K	1,800

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AIMD on your watchlist

Track score changes the day Ainos, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AIMD a good stock to buy?

13F Pro's AI-powered analysis of Ainos, Inc. (AIMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIMD are available on the AIMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AIMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ainos, Inc.'s investment landscape.